Non-steroidal anti-inflammatory drug use and brain tumour risk: A case-control study within the Clinical Practice Research Datalink

Cancer Causes and Control

Volumn 24, Issue 11, 2013, Pages 2027-2034

  Bannon, F J ^a   O'Rorke, M A ^a   Murray, L J ^a   Hughes, C M ^b   Gavin, A T ^a   Fleming, S J ^c   Cardwell, C R ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Aspirin; Brain tumour; Clinical Practice Research Datalink; Glioma; Meningioma; Non steroidal anti inflammatory drug; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; ALLERGY; ARTHRALGIA; ARTICLE; CANCER DIAGNOSIS; CANCER MODEL; CANCER RISK; CLINICAL PRACTICE; CLINICAL RESEARCH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG MEGADOSE; DRUG USE; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; GLIOMA; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENINGIOMA; OSTEOARTHRITIS; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; UNITED KINGDOM;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GLIOMA; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS;

EID: 84886782803     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0279-9     Document Type: Article

References (44)

1. Cancer Research UK (2012) Brain and other CNS tumour statistics. http://info.cancerresearchuk.org/cancerstats/types/brain/uk-brain-and-cns- tumour-statistics
2. McKinney PA (2004) Brain tumours: incidence, survival and aetiology. J Neurol Neurosurg Psychiatry 75:ii12-ii17. doi: 10.1136/jnnp.2004.040741
3. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Nuerol 2:494-503. doi: 10.1038/ncpneuro0289
4. Wrensch M, Minn Y, Chew T et al (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278-299. doi: 10.1093/neuonc/4.4.278
5. Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99:307-314. doi: 10.1007/s11060-010-0386-3
6. Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113-120
7. Blitshteyn S, Crook JE, Jaeckle KA (2008) Is there an association between meningioma and hormone replacement therapy. J Clin Oncol 26:279-282
8. Pines A (2011) Hormone therapy and brain tumours. Climacteric 14:215-216
9. Linos E, Raine T, Alonso A, Michaud D (2007) Atopy and risk of brain tumours: a meta-analysis. J Natl Cancer Inst 99:1544-1550
10. Ragel BT, Jensen RL, Gillespie DL et al (2005) Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application. J Neurosurg 103:508-517
11. Kato Y, Nishihara H, Mohri H, et al. (2012) Clinicopathological evaluation of cyclooxygenase-2-expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma. Brain Tumor Pathol (epub ahead of print)
12. Ragel BT, Jensen RL, Couldwell WT (2007) Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors. Neurosurg Focus 23:E7
13. Buccoliero AM, Castiglione F, Rossi Deggli'Innocenti D et al (2007) Cyclooxygenase-2 (COX-2) overexpression in meningioma: real time PCR and immunohistochemistry. Appl Immunohistochem Mol Morphol 15:187-192
14. Pistolesi S, Boldrini L, Gisfredi S et al (2007) Expression of cyclooxygenase-2 and its correlation with vasogenic brain edema in human intracranial meningiomas. Cancer Invest 25:555-562
15. El-Sayed M, Taha MM (2011) Immunohistochemical expression of cyclooyxgenase-2 in astrocytoma: correlation with angiogenesis, tumour progression and survival. Turk Neurosurg 21:27-35
16. Temel SG, Kahveci Z (2009) Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. J Mol Histol 40:369-377
17. Sareddy GR, Geeviman K, Ramulu C, Babu PP (2011) The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway. J Neurooncol 106:99-109
18. Joki T, Heese O, Nikas DC et al (2000) Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-II inhibitor, NS-398. Cancer Res 60:4926-4931
19. King JG, Khalili K (2001) Inhibition of human brain tumour cell growth by the anti-inflammatory drug, flurbiprofen. Oncogene 20:6864-6870
20. Wakimoto N, Wolf I, Yin D et al (2008) Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res 68:6978-6986
21. Xu K, Gao H, Shu HK (2011) Celecoxib can induce vascular endothelial growth factor expression and tumour angiogenesis. Mol Cancer Ther 10:138-147
22. Fujita M, Kohanbash G, Fellows-Mayle W et al (2011) COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 71:2664-2674. doi: 10.1158/0008-5472.CAN-10-3055
23. Ragel BT, Jensen RL, Gillespie DL et al (2007) Celecoxib inhibits meningioma tumour growth in a mouse xenograft model. Cancer 109:588-597
24. Hwang DH, Fung V, Dannenberg AJ (2002) National Cancer Institute workshop on chemopreventative properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and independent mechanisms. Neoplasia 4:91-97
25. Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6:130-140. doi: 10.1038/nrc1801
26. Nathoo N, Barnett GH, Golubic M (2004) The eicosanoid cascade: possible role of gliomas and meningiomas. Mol Pathol 57:6-13
27. Hwang S-L, Lee K-S, Lin C-L et al (2004) Effect of aspirin and indomethacin on prostaglandin E2 synthesis in C6 glioma cells. Kaohsiung J Med Sci 20:1-2
28. Kim SR, Bae MK, Kim JY et al (2009) Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun 387:342-347. doi: 10.1016/j.bbrc.2009.07.022
29. Daugherty SE, Moore SC, Pfeiffer RM et al (2011) Nonsteroidal anti-inflammatory drugs and glioma in the NIH-AARP Diet and Health Study cohort. Cancer Prev Res 4:2027-2034. doi: 10.1158/1940-6207.CAPR-11-0274
30. Friis S, Sorensen HT, McLaughlin JK et al (2003) A population-based cohort study of the risk of colorectal cad other cancers among users of low-dose aspirin. Br J Cancer 88:664-668
31. Gaist D, García-Rodríguez LA, Sørensen HT et al (2013) Use of low-dose aspirin and non-aspirin nonsteroidal anti-inflammatory drugs and risk of glioma: a case-control study. Br J Cancer 108:1189-1194
32. Scheurer ME, Amirian ES, Davlin SL et al (2011) Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies. Int J Cancer 129:2290-2296. doi: 10.1002/ijc.25883
33. Sivak-Sears NR, Schwartzbaum JA, Miike R et al (2004) Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. Am J Epidemiol 159:1131-1139. doi: 10.1093/aje/kwh153
34. Ferris J, McCoy L, Neugut AI et al (2012) HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer 131:E1031-E1037
35. Chen C, Xu T, Chen J et al (2011) Allergy and risk of glioma: a meta-analysis. Eur J Neurol 18:387-395. doi: 10.1111/j.1468-1331.2010.03187.x
36. Fan ZX, Shen J, Wu YY, Yu H, Zhu Y, Zhan RY (2013) Hormone replacement therapy and risk of meningioma in women: a meta-analysis. Cancer Causes Control 24(8):1517-1525
37. Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294:47-55
38. Rothwell PM, Fowkes FG, Belch JF et al (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41
39. Boggon R, van Staa TP, Chapman M et al (2013) Cancer recording and mortality in the general practice research database and linked cancer registries. Pharmacoepidemiol Drug Saf 22:168-175
40. Proprietary Association of Great Britain (2013) Annual review 2012. http://www.pagb.co.uk/publications/annualreview.html
41. Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast or colon cancer. Pharmacotherapy 22:303-309
42. Yood UM, Campbell UB, Rothman KJ et al (2007) Using prescription claims data for drugs available over-the-counter (OTC) y. Pharmacoepidemiol Drug Saf 16:961-968. doi: 10.1002/pds
43. Yang Y, Pharmd SH, Propert K et al (2008) Chronic statin therapy and the risk of colorectal cancer y. Pharmacoepidemiol Drug Saf 17:869-876. doi: 10.1002/pds
44. Perry M (2011) Medication, polypharmacy and compliance in older people. Br J Health Care Assist 5:433-435